Lowering Drug Costs For American Families Act

Lowering Drug Costs For American Families Act

Date Introduced: November 20, 2025

Status: Not passed yet, still currently a proposed legislation

Background: High prescription drug prices in the United States can create major affordability issues for all citizens, especially for seniors or people with illnesses. In 2022, the Inflation Reduction Act addressed this issue by allowing limited Medicare price negotiations. However, some faults included drug companies still being able to raise their prices and only a small number of drugs being eligible for negotiations. And to expand on these reforms, the Lowering Drug Costs for American Families was introduced.

Summary: House of Democratic Health committee leaders introduced the "Lowering Drug Costs for American Families Act” in order to provide more affordability in prescription drugs. This act builds on earlier reforms, such as the Inflation Reduction Act, to expand on the power to control drug costs while also increasing access and cost effective prescribed drugs for patients. Key provisions of these bills include expanding Medicare negotiations, allowing a greater number of medications to be under government-set prices. It also aims to extend these negotiated prices to individuals with private insurance. Additionally, the act aims to cap out-of-pocket costs of ~$35 a month for an insulin cap, which is critical for individuals who have diabetes. It also aims to penalize pharmaceutical companies that raise drug prices faster than inflation to discourage sudden and excessive price increases. Lastly, it works to close loopholes that companies use, requiring more transparency in medical and drug practices. Together, the act represents an effort to create more transparency and regulation of the prescription drug market in the United States.

Impact: The potential positive impacts that this act would have are lowering medication costs for patients which makes prescriptions more affordable by reducing any financial strain. It would increase healthcare accessibility to allow more individuals to obtain necessary treatments for health maintenance. Additionally, the act could also decrease federal healthcare spending in Medicare.

Critics, though, argue that reduced profits can discourage investment in research, potentially slowing down the creation of new treatments or medications or innovations. Others might believe that increasing government involvement in drug practicing can disrupt the free market or lead to unintended consequences in the healthcare system, like limited availability of certain medications.

Sources:

? https://democrats-waysandmeans.house.gov/media-center/press-releases/house-democratic-health-leaders-introduce-bill-lower-prescription-drug

? https://www.gao.gov/products/gao-25-106996

? https://www.medicaleconomics.com/view/medicare-s-100-billion-decision-biologics-biosimilars-and-prescription-drug-price-negotiations